Biotechnology

ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS

Adaptimmune Therapeutics PLC released FY2024 Q2 earnings on August 13, 2025 (EST), actual revenue USD 128.23 M (forecast USD 44.76 M), actual EPS USD 0.24

Adaptimmune Therapeutics PLC released FY2025 Semi-Annual Earnings on August 13 (EST), actual revenue USD 20.96 M, actual EPS USD -0.2999

Adaptimmune Therapeutics PLC released FY2024 Semi-Annual Earnings on August 13, 2025 (EST), with actual revenue of USD 133.91 M and EPS of USD 0.06

Adaptimmune Therapeutics PLC released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 13.68 M (forecast USD 8.963 M), actual EPS USD -0.1199

Adaptimmune Therapeutics PLC released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 7.285 M (forecast USD 6.551 M), actual EPS USD -0.1851

Adaptimmune Therapeutics PLC released FY2024 Q1 earnings on May 13, 2025 (EST), actual revenue USD 5.678 M (forecast USD 20.48 M), actual EPS USD -0.2005

Adaptimmune Therapeutics PLC released FY2022 earnings on March 24, 2025 (EST), actual revenue USD 27.15 M (forecast USD 25.46 M), actual EPS USD -1.0263

Adaptimmune Therapeutics PLC released FY2023 earnings on March 24, 2025 (EST), actual revenue USD 60.28 M (forecast USD 86.05 M), actual EPS USD -0.5663

ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS released FY2024 Annual Earnings on March 24, 2025 (EST), actual revenue USD 178.03 M (forecast USD 182.99 M), actual EPS USD -0.3

Adaptimmune Therapeutics PLC released FY2024 Q4 earnings on March 24, 2025 (EST), actual revenue USD 3.222 M (forecast USD 8.181 M), actual EPS USD -0.309

Adaptimmune Therapeutics PLC released FY2023 Q4 earnings on March 24, 2025 (EST), actual revenue USD 231K (forecast USD 25.96M), actual EPS USD -0.2109

Adaptimmune Therapeutics PLC released FY2024 9 Months Earnings on November 13 (EST), actual revenue USD 174.81 M, actual EPS USD -0.0294

Adaptimmune Therapeutics PLC released FY2023 Q3 earnings on November 13 (EST), actual revenue USD 7.319 M (forecast USD 15.14 M), actual EPS USD -0.2014

Adaptimmune Therapeutics PLC released FY2024 Q3 earnings on November 13 (EST), actual revenue USD 40.9 M (forecast USD 20.49 M), actual EPS USD -0.0688

Akanda

Axe Compute

Toro

eLong Power

AdvisorShares MSOS 2x Daily ETF

Inhibrx Biosciences

TAVIA ACQUISITION CORP COM USD0.0001 (SUBS/RIGHTS)

Newsmax

GameSquare

Beam Global

Kiniksa Pharmaceuticals

Rigel Pharma

MiMedx

CapForce Inc.

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS(ADAPY.US)

ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS Stock Performance Chart